Interestingly, the same study demonstrated that NRASQ61 mutation can be detected with high-sensitivity ddPCR in the plasma of patients with tissue BRAF mutations, raising the hypothesis that NRASQ61 mutations might co-exist at low frequency in bulky tumours and suggests plasma ctDNA as a complementary genotyping tool too [92]. Here, BRAF is linked to neoplasm.